People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently approved only for type 2 diabetes, according to results from a small trial.

CHMP recommends a label update for Novo Nordisk's Ozempic after the STRIDE study shows walking improvements in T2D patients with PAD.

In addition, Novo Nordisk said it has filed for a label expansion for Rybelsus with the EMA and FDA. This could potentially make Rybelsus the first and only oral GLP-1 RA with proven ...

Q: My doctor is suggesting that I try taking one of those new weight loss drugs -- off-label -- to help me cut down on my alcohol consumption. Does this make any sense? -- Pat R., Ann Arbor, Michigan ...

Nation and World Popular ‘miracle’ weight loss drug is causing people to lose their vision, lawsuits claim Published: Jun. 20, 2025, 11:05 a.m.

A simple oversight could end up costing Danish pharma giant Novo Nordisk A/S (NYSE: NVO) billions in potential losses on its blockbuster weight-loss and diabetes drug, Ozempic.